Tags Archive Navigation
icon
-
Media ReleaseNovartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
-
Media ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Media ReleaseNovartis completes divestment of ‘front of eye’ ophthalmology assets
-
Media ReleaseSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
-
Media ReleaseNovartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
-
Media ReleaseNovartis confirms Sandoz Spin-off for October 4, 2023
-
Media ReleaseNovartis shareholders approve the proposed 100% Spin-off of Sandoz
-
Media ReleaseLes actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
-
Media ReleaseAktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
-
Media ReleaseSandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
-
StoryTreatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
-
Media ReleaseNovartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 32
- › Next page